2025 was a defining year for RIVANNA as we connected with anesthesiology providers, healthcare innovators, and research leaders across the United States. From clinical symposia and pitch competitions to academic conferences and a moment in Times Square, our mission remained constant: advancing AI-based ultrasound imaging solutions that move innovation from unmet need to standard of care.
Medical imaging innovation meets recognition
One of our biggest achievements of 2025 came early in the year through our participation in the MedTech Innovator program. RIVANNA’s path through the program began in April 2025 at the East Coast Pitch Event in College Park, Maryland, where we competed for advancement into the MedTech Innovator (MTI) Accelerator cohort. Our selection to this elite group of companies validated our approach to solving unmet clinical challenges through AI-guided ultrasound innovation.
Advancing to the finalist stage of the Early-Stage Grand Prize competition placed our platforms in front of strategic partners and investors who understand the clinical and economic value of technologies that improve patient outcomes. Our participation in Life Science Intelligence (LSI) USA25 extended these conversations with industry leaders evaluating technologies with real market potential.
The visual highlight arrived when RIVANNA’s logo illuminated the NASDAQ Tower in Times Square — a moment connected to our MedTech Innovator achievements that represented our technology’s potential to shape markets and improve patient outcomes across multiple clinical indications and medical specialties.
Clinical education and provider engagement
Throughout the year, RIVANNA’s presence at major medical conferences demonstrated our focus on provider education and clinical evidence.
At the 2025 Military Health System Research Symposium (MHSRS), we engaged with military medical professionals who demand rugged, reliable technology that can perform in challenging environments. The ANESTHESIOLOGY 2025 Conference and AANA Annual Congress in Nashville connected us with anesthesiology providers managing increasingly complex obstetric and surgical cases. These conversations provided invaluable feedback on our product development, ensuring we design solutions that improve workflow efficiency in real clinical settings. RIVANNA’s partnership with the American Society of Anesthesiologists’ Innovator Supporter Program underscores a collaborative commitment to advancing innovations that improve patient safety and clinical outcomes.
The Society for Obstetric Anesthesia and Perinatology (SOAP) 2025 conference proved particularly meaningful. With cesarean delivery rates increasing and maternal obesity affecting more pregnant patients, obstetric anesthesia providers face anatomical challenges where traditional palpation methods prove unreliable. Meeting with clinicians at SOAP allowed us to gather critical insights that directly inform our product roadmap, centered on how ultrasound-guided neuraxial anesthesia can support first-attempt success while integrating seamlessly into demanding perioperative workflows.
Expanding the conversation
Regional meetings like the Society for Academic Emergency Medicine (SAEM) Western Regional Meeting and American Institute of Ultrasound in Medicine (AIUM) 2025 allowed deeper engagement. These communities understand imaging’s role in procedural precision, as they’ve witnessed how visualization can improve outcomes across clinical applications.
MedTech World Bay Area 2025 brought together innovators addressing healthcare’s most pressing challenges. The conversations there reinforced what providers tell us daily: technologies succeed when they solve real problems without adding complexity to already-demanding workflows.
Regulatory and intellectual property milestones
Beyond industry recognition, 2025 marked significant regulatory achievements. RIVANNA secured FDA 510(k) clearance for the Accuro 3S diagnostic ultrasound system and SpineNav-AI software in July, followed by clearance for the Accuro 3S Needle Guide Kit in December. These clearances validate years of engineering development and clinical collaboration.
RIVANNA’s intellectual property portfolio, which includes more than 75 patents and patents pending protecting ultrasound-based innovations, expanded in 2025 with the acquisition of US Patent #11,432,801 B2 for an advanced ultrasound-guided needle insertion system. This foundational technology, developed in collaboration with Dr. Charles Y. Kim at Duke University, demonstrates RIVANNA’s commitment to translating academic research into commercially viable clinical solutions.
Looking ahead to 2026
Every conference, every demonstration, and every provider conversation in 2025 reinforced RIVANNA’s purpose. We’ve earned the trust of global and government partners by translating real clinical challenges into imaging solutions that improve workflows, support better decision-making, and lead to better patient outcomes. Our AI-driven, radiation-free platforms are closing critical gaps in care and setting new standards for safety, speed, and accessibility.
As we close 2025 and look toward 2026, RIVANNA remains committed to the providers who trust Accuro in their most challenging cases — and to the patients who depend on successful neuraxial placement. Accuro has meaningfully reshaped the neuraxial anesthesia market. Accuro is not an isolated success; it’s the first chapter in a clear strategic arc. Our flagship Accuro system demonstrated how targeted innovation can redefine clinical practice. We are applying the same disciplined, problem-solving approach to emerging needs across neuraxial anesthesia, emergency medicine, and beyond.
Join our newsletter for more updates on innovations in medical imaging.